# CREATE Medicines

> CREATE Medicines is a Cambridge, Massachusetts clinical-stage biotech building in vivo immune programming - therapies that use an mRNA-lipid nanoparticle platform to turn a patient's own T cells, NK cells, and myeloid cells into chimeric antigen receptor (CAR) cells directly inside the body, rather than extracting and re-engineering them in a lab. Formerly Myeloid Therapeutics, the company rebranded in October 2025 as its pipeline expanded beyond myeloid cells and cancer into autoimmune disease and fibrosis. Its repeat-dosable, off-the-shelf approach aims to make CAR therapy cheaper and more scalable than conventional cell therapy, and the company says it has dosed more than 50 patients - among the largest clinical datasets for in vivo CAR to date.

- **Founded:** 2021
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Daniel Getts (CEO, Co-Founder, Board Director)
- **Team size:** ~42 employees
- **Products:** In Vivo Multi-Immune Programming Platform, CRT-402, CRT-403, MT-302, MT-303
- **Notable:** Raised a $122 million Series B in May 2026, bringing total funding to roughly $245 million., Reports dosing more than 50 patients across its in vivo CAR clinical programs - among the largest clinical datasets in the in vivo CAR field., Demonstrated first-in-human evidence of tolerable, repeat dosing of in vivo-programmed immune cells.

## Products & services

- **In Vivo Multi-Immune Programming Platform** — A proprietary mRNA-lipid nanoparticle (mRNA-LNP) platform that delivers CAR-encoding RNA to program T cells, NK cells, and myeloid cells directly inside the body, with optional retrotransposon-mediated stability for more durable expression.
- **CRT-402** — Next-generation CD19-targeted in vivo CAR-T program for autoimmune disease; showed deep B-cell depletion in non-human primates with repeat-dosing potential.
- **CRT-403** — Dual CD19 x BCMA CAR-T program using retrotransposon (RetroT) stability, designed for broader reach in refractory autoimmune conditions.
- **MT-302** — TROP2-targeted in vivo myeloid CAR in clinical development for frontline gastroesophageal junction (GEJ) cancer.
- **MT-303** — GPC3-targeted in vivo myeloid CAR in clinical development for frontline hepatocellular carcinoma (HCC).
- **MT-304** — HER2-targeted multi-immune in vivo CAR engaging NK and myeloid cells, in clinical development for HER2-positive solid tumors including breast cancer.
- **CRT-401** — Dual HER2 x TROP2 multi-immune CAR engaging T, NK, and myeloid cells.

## Achievements

- Raised a $122 million Series B in May 2026, bringing total funding to roughly $245 million.
- Reports dosing more than 50 patients across its in vivo CAR clinical programs - among the largest clinical datasets in the in vivo CAR field.
- Demonstrated first-in-human evidence of tolerable, repeat dosing of in vivo-programmed immune cells.
- Rebranded from Myeloid Therapeutics to CREATE Medicines in October 2025 after expanding from myeloid-only to multilineage immune programming.
- Advanced multiple clinical oncology programs (MT-302, MT-303, MT-304) and expanded into autoimmune disease with CRT-402.

## Latest updates

- **2026-05** — Announced $122M Series B co-led by Newpath, ARCH, and Hatteras to advance its in vivo CAR pipeline in autoimmune disease and oncology; added Ron Philip as Executive Chairman and new board members from ARCH and Newpath.
- **2025-10** — Rebranded from Myeloid Therapeutics to CREATE Medicines, reflecting a shift from myeloid-only to multilineage (T, NK, myeloid) in vivo immune programming.

## Links

- Website: https://createmedicines.com
- LinkedIn: https://www.linkedin.com/company/createmedicines
- Twitter/X: https://x.com/CREATEMedicines
- Bluesky: https://bsky.app/profile/createmedicines.bsky.social

---

Profile page: https://yespress.io/create-medicines
Published by YesPress — https://yespress.io
Last updated: 2026-07-21